Companies are collaborating to set a new standard for patient-centric digital clinical trials

BRUSSELS And PLEASANTON, CALIFORNIA., May 23, 2023 /PRNewswire/ — Veeva systems VEEV And UCB, a global biopharmaceutical company, today announced a collaboration that will focus on technology-driven solutions to improve patient experience and study efficiency. The cooperation will be taken over by UCB Veeva ePRO And Veeva eConsentto provide study participants with a patient-centric, digital experience and to actively influence the strategic direction of these and other applications based on the insights. Together, Veeva and UCB aim to set a new industry standard for digital clinical trials with multiple applications that address the unique needs of patients.

“The partnership between UCB and Veeva presents a significant opportunity to advance advances in clinical trial delivery,” said Iris Löw-Friedrich, Executive Vice President and Chief Medical Officer at UCB. “By providing digital clinical trials, we reduce the burden on participants and sites, improve trial accessibility and ensure that patients are at the center of everything we do.”

Veeva ePRO simplifies the design, management, and completion of Electronic Patient Records (ePRO) with seamless data flow between sponsors, sites, and patients. Veeva eConsent simplifies the setup, completion, and verification of consent for patients, sites, and study teams. Both applications are available to patients via MyVeeva for patients, which provides a central access point for all clinical trial actions, planning and communications. Veeva ePRO and Veeva eConsent are part of Veeva Vault Clinical Suitea set of built-in capabilities that simplify the clinical trials technology landscape for both clinical operations and clinical data management.

“We are excited to partner with UCB to advance patient-centric digital trials,” said Veeva CEO Peter Gasner. “Your contribution will help advance Veeva’s approach to solutions that…